TARGET GLYCEMIC CONTROL AND THE INCIDENCE OF DOCUMENTED SYMPTOMATIC HYPOGLYCEMIA IN INSULIN NAÏVE SUBJECTS WITH TYPE 2 DIABETES FAILING ON ORAL HYPOGLYCEMIC AGENT(S) AND TREATED WITH LANTUS (INSULIN GLARGINE) OR LEVEMIR (INSULIN DETEMIR): MULTICENTER, MULTINATIONAL, RANDOMIZED, OPEN-LABEL, COMPARATIVE, PARALLEL-GROUP STUDY
Latest Information Update: 12 Apr 2022
At a glance
- Drugs Insulin glargine (Primary) ; Insulin detemir
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms L2T3
- Sponsors Sanofi
- 01 Apr 2018 Results of pooled analysis of Asian patients included in this and other six trials assessing the impact of patient baseline covariates on the required dose of basal insulin and treatment response for the improved management of Asian patients with type 2 diabetes published in the Diabetes Therapy
- 01 Oct 2010 Results of a substudy published in Diabetes, Obesity and Metabolism. The analysis examined the effects of continuing versus discontinuing insulin secretagogues on glycaemic control outcomes.
- 03 Mar 2010 Results published early online in Diabetes Care.